FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:586-587 February 20, 1997 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Geerts, W. H. PubMed Citation

To the Editor: We view with concern the claim of Geerts et al. (Sept. 5 issue)¹ that the potent anticoagulant low-molecular-weight heparin can safely be used as routine prophylaxis against deep venous thrombosis in trauma victims. The study compared low-dose heparin with low-molecular-weight heparin in a cohort of 265 patients. The authors found that deep venous thrombosis occurred at a higher rate in the low-dose–heparin group (60 of 136 patients, or 44 percent) than in the low-molecular-weight–heparin group (40 of 129, or 31 percent; P = 0.014). Thus, 18 (60 minus 31 percent of 136) cases of deep venous thrombosis . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.